Puma Biotechnology Q3 2023 net income $5.8M, reverses prior-year loss; revenue $56.1M

PUMA BIOTECHNOLOGY, INC.

2023-Q3 EPS reported $0.20 revenue$163,459,000

Product revenue net $51.6M (down 5% YoY from $54.3M); total revenue $56.1M.
GAAP net income $5.8M ($0.12/diluted) vs net loss $0.4M in Q3 2022.
Non-GAAP adjusted net income $8.3M ($0.17/diluted) vs $2.5M prior year.
Cash and securities $85.0M; net cash from operations $10.7M in Q3.
Q4 product revenue guidance $56-59M; FDA accepted IND for alisertib, granted orphan drug designation for SCLC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

PUMA BIOTECHNOLOGY, INC. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 2, 2023, Puma Biotechnology, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

PUMA BIOTECHNOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001437749-23-030014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.